mynth
← DATABASE
04/2019100%

Cytosport acquired by Pepsico

UNITED STATES Food Processing / Food Products EV $300–700M

Context

PepsiCo announced the completion of its acquisition of CytoSport on 30 September 2026. The transaction, valued at an enterprise value of $300–700M, transfers ownership of the Muscle Milk and Evolve sports‑nutrition brands from Hormel Foods to PepsiCo. The deal was structured as a cash sale of the CytoSport business, with the purchase price of $465 million subject to working‑capital adjustments. Hormel, which originally acquired CytoSport in 2014 for about $450 million, will receive the proceeds and retain no stake in the business. PepsiCo, the parent of Gatorade, said the transaction aligns with its tuck‑in acquisition strategy and expands its portfolio of convenient sports‑nutrition products.

In the past, Cytosport was acquired by Hormel Foods in 2014 as part of its expansion strategy.

-> Deep-dive in AgriFood market trends

Target

Founded in 2014 through Hormel Foods' acquisition of CytoSport Holdings, Inc., the business manufactures sports nutrition products under the Muscle Milk brand. Its portfolio spans ready-to-drink beverages, protein-based powders, sports nutrition bars and energy chews. In 2017, CytoSport introduced Evolve, a plant-based and vegan protein line featuring shelf-stable shakes, powders and bars made with pea protein. The company targets athletes, fitness enthusiasts and consumers seeking convenient protein options across retail channels. Its dual-brand approach pairs a mainstream sports nutrition label with a plant-based alternative, addressing a broadening range of dietary preferences within the category.

Ent. Value

$300–700M

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

15x–25x

EV / EBIT

[members only]

Historical Financials (USD)

Year
Rev
EBITDA
EBIT
2019
$250–500M
$25–50M
[members only]
2018
$250–500M
$25–50M
[members only]

Other operations with Cytosport

Other operations with Cytosport
DateAcquirerTargetCountrySector
08/2014HORMEL FOODSCYTOSPORTUNITED STATESFood Products

Other operations with Pepsico

Other operations with Pepsico
DateAcquirerTargetCountrySector
01/2025PEPSICOSIETE FOODSUNITED STATESBakery / Pastry
10/2018PEPSICOHEALTH WARRIORUNITED STATESFood Products
08/2018PEPSICOSODASTREAMUNITED STATESConsumer Products

Similar deals in Food Processing

Similar deals in Food Processing
DateAcquirerTargetCountrySector
06/2019MONDELEZ INTERNATIONALPERFECT SNACKSUNITED STATESFood Products
06/2019HEINEKENOEDIPUSNETHERLANDSWines & Spirits
04/2019THE FERRERO GROUPKELLOGG COOKIES AND FRUIT SNACKSUNITED STATESBakery / Pastry
04/2019DANONEMICHEL ET AUGUSTINFRANCEFood Products
04/2019PAI PARTNERSECOTONENETHERLANDSFood Processing
02/2019SALT CREEK CAPITALTHE FLAVOR OF CALIFORNIAUNITED STATESFood Products
02/2019PERMIRAHANA GROUPFRANCEFood Products
02/2019BRIMSTONE INVESTMENTCLOVER INDUSTRIESSOUTH AFRICADairy
01/2019ASAHI EUROPEFULLERS BEER BUSINESSUNITED KINGDOMWines & Spirits
12/2018MADEMOISELLE DESSERTSDELICE DES 7 VALLEESFRANCEBakery / Pastry

REFERENCES

Valuation range: EV $300–700M

Revenue range: $250–500M

EBITDA range: $25–50M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 15x - 25x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Cytosport by Pepsico are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

FAQ

What transaction does this page cover?

This page covers Pepsico’s acquisition of 100% of Cytosport, an American company specialised in Food Products, in 2019. This followed an earlier holding cycle initiated in August 2014, when the company was acquired by Hormel Foods.

How was the acquisition of Cytosport by Pepsico valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the $300–700M band, its EV/EBITDA multiple within the 15x - 25x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Cytosport’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Cytosport generated annual revenue estimated in the $250–500M range and EBITDA in the $25–50M bracket (FY 2019). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction intelligence is supported by independent reporting from specialized financial publications, alongside a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.